Go into your next round with the value story your acquirer will use.
You don't have a 30-person Market Access function. You have one or two brilliant people, and a board that expects answers a Big Pharma team would need a quarter to assemble. Knowledgeable gives that lean team the capability of a department, from preclinical positioning to launch, so every Series C, business development conversation and partner meeting opens with the asset narrative your buyers will adopt verbatim.
"Plan a 12-week pre-launch value-story programme for our Phase 2 NASH asset."
The results show up before the next board meeting.
One system across the whole asset life.
No tool sprawl, no re-learning. The work your team did at Phase 1 powers the dossier you file at launch and the diligence pack your acquirer opens at term sheet. The same evidence base. The same audit trail.
Preclinical positioning your board can defend
Indication scoping, competitive landscape and TPP drafting. Before you spend a million on a Phase 1 competing treatment your CMO will regret picking.
Clinical strategy anchored to payer reality
Endpoint selection grounded in HTA precedent. Competing treatment choice anchored to what reimbursement bodies have actually accepted. Trial design that anticipates the AMNOG and NICE conversation, not retrofits to it after readout.
Launch, business development and diligence, from one evidence base
Value story, payer dossier, HTA submission, pricing corridor and the data room your acquirer's bankers will tear through. All generated from the same evidence, all kept live as the data lands.
Your asset story never goes stale between rounds.
As trials read out, real-world evidence accumulates and competitors move, Knowledgeable keeps your value story, TPP and HTA positioning continuously current. No scramble to rebuild the deck the weekend before the board call, the business development pitch or the diligence room opens.
No standing army of consultants on the cap table.
Every claim source-linked, every number defensible.
Bring department-grade output to your next milestone.
Go into your next round preparedFrequently asked questions.
Diligence-ready without the enterprise drag.
SSO, mandatory 2-factor, full audit trail and EU/UK data residency on every plan. Move at biotech speed without giving your lead investor or your future acquirer's diligence team a reason to pause the conversation.